Vaxart, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Vaxart, Inc. (VXRT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-20
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.10%.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.00%, a 100.00% decline from fiscal 2022.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 1.50%, a 650.00% increase from fiscal 2021.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.20%, a 90.91% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.10% 10-K · filed 2025-03-20 | |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-20 | 1.10% 10-K · filed 2024-03-14 |
| 2022-12-31 | 1.50% 10-K · filed 2024-03-14 | -1.50% 10-K · filed 2023-03-15 |
| 2021-12-31 | 0.20% 10-K · filed 2023-03-15 | |
| 2020-12-31 | 2.20% 10-K · filed 2022-02-24 | |
| 2019-12-31 | -3.70% 10-K · filed 2022-02-24 | |
| 2018-12-31 | -2.50% 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |